Funding for this research was provided by:
Yorkshire Cancer Research (L399)
Received: 17 January 2020
Accepted: 13 July 2020
First Online: 18 July 2020
Ethics approval and consent to participate
: This study received ethical approval from NRES Yorkshire and the Humber- Leeds East Research Ethics Committee (REC Ref: 16/YH/0407), and is registered in ExternalRef removed database.
: Not applicable.
: The authors declare that they have no competing interests. Professor Velikova reports personal fees from Roche, personal fees from Eisai, personal fees from Novartis, personal fees from Pfizer, grants from NIHR UK Government, grants from Breast Cancer NOW, grants from EORTC, outside the submitted work.